Lung Cancer

Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer

November 19, 2022

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

November 15, 2022

The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.

Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)

November 08, 2022

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.